{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigvvsag36lux3y5pf7uxy6t2zthds3l546rltpcdnn2etdnyeccju",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mnaifx2cqqa2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibbrj7sjypegmmbjd7nke3pds55q3bzikfyaodnjmfzu7f7fef2qe"
    },
    "mimeType": "image/webp",
    "size": 53480
  },
  "path": "/releases/2026/05/260530053426.htm",
  "publishedAt": "2026-06-01T09:25:47.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk. Researchers found that just one year of treatment with the immune-targeting drug abatacept delayed the onset of rheumatoid arthritis by up to four years, with benefits lasting long after treatment ended.",
  "title": "This drug delayed rheumatoid arthritis for years after treatment ended"
}